LTLotte C. Terpstra

Lotte C. Terpstra

*This is an algorithmically generated author record based on publicly available information.

Lotte C. Terpstra has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • J. Altenburg

    Department of Pulmonary Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

    4 shared publications
  • Wim G. Boersma

    Department of pulmonary medicine Northwest Clinics Alkmaar Alkmaar The Netherlands

    4 shared publications
  • Inez Bronsveld

    Department of pulmonary medicine University Medical Centre Utrecht Utrecht The Netherlands

    3 shared publications
  • Josje Altenburg

    Department of Pulmonary Diseases, Amsterdam Medical Center, Amsterdam, The Netherlands

    3 shared publications
  • H. G. M. Heijerman

    Department of Pulmonary Diseases, University Medical Centre Utrecht and Utrecht University, Utrecht, The Netherlands

    2 shared publications
  • H. J. Doodeman

    Department of Northwest Academy, Northwest Clinics, Alkmaar, The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community‐Acquired Pneumonia (CAP)

    by Lisa Hessels, Ruud Duijkers, Marianne Schoorl, Lotte Terpstra, Willemien Thijs, Wim Boersma

    Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community‐acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.Methods: A total of 204 hospitalised CAP patients were enrolled. C‐reactive protein (CRP), procalcitonin (PCT), suPAR, CURB‐65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.Results: Among 204 patients, 174 (85%) had non‐severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88–1.21; AUC 0.53). Unlike the PSI and CURB‐65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB‐65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30‐day mortality (HR 1.51, AUC 0.68).Conclusions: The prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB‐65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30‐day mortality, its utility for predicting LOS or TTCS is low.Trial Registration: ClinicalTrials.gov identifier: NCT01964495


  • Open Access

    Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial

    by Lotte C. Terpstra, Daphne van der Geest, Inez Bronsveld, Harry Heijerman, Wim G. Boersma

    Introduction: Tobramycin inhalation solution (TIS) is a treatment option for patients with frequent exacerbations of bronchiectasis. A possible side effect of TIS is the development of chronic cough and bronchospasm, whereby the guidelines suggest a (in hospital) tolerance test with the first dose of TIS. However, data on respiratory adverse events are not consistent. In the present analysis from the BATTLE study (NCT02657473), we evaluated the added value of the tolerance test and aimed to observe the development of inhaled treatment related bronchial hyperreactivity.Methods: Fifty‐seven patients from the BATTLE study were analyzed. Patients were randomized to receive TIS or placebo OD for 1 year. A tolerance test was performed with spirometry measurements before and after the first dose and with a bronchodilator in advance. Adverse events were strictly monitored.Results: Fifty‐seven patients (100%) passed the tolerance test with no decrease in spirometry measurements or development of local intolerability. During the study treatment, a total of five TIS‐treated patients (17.8%) withdrew due to airway hyperresponsiveness after a mean of 9.2 (SD13.9) weeks and one placebo‐treated patient (3.5%) after 2 weeks (TIS vs. placebo; p = 0.66). The other TIS‐related adverse events were not clinically significant.Conclusion: The use of inhaled medication is well tolerated in the heterogenous bronchiectasis population, without signs of airway hyperresponsiveness after the first dose of inhaled medication. From this observation, it can be concluded that there is no additional value for this advised tolerance test. However, closely monitoring on adverse effects during the first weeks after starting TIS is recommended.


  • Open Access

    The effect of azithromycin on sputum inflammatory markers in bronchiectasis

    by L. C. Terpstra, J. Altenburg, H. J. Doodeman, Y. S. Sabogal Piñeros, R. Lutter, H. G. M. Heijerman, W. G. Boersma

    Background: Long term macrolide treatment has been found beneficial in bronchiectasis (BE) -pathogical bronchial dilatation- possibly due to a combined anti-bacterial and immunomodulatory effect. The exact mechanism of inflammatory response is unknown. Here, we investigated the effect of maintenance macrolide treatment on the inflammatory response in BE. In addition, we assessed the inflammatory profile in BE in relation to disease severity. Methods: During the BAT randomized controlled trial (investigating the effect of 1 year of azithromycin (AZM) in 83 BE patients), data on BE severity, lung function and sputum microbiology was collected. For the current study, a wide range of inflammatory markers were analysed in 3- monthly sputum samples in all participants. Results: At baseline, marked neutrophilic but also eosinophilic inflammation was present in both groups, which remained stable throughout the study and was not affected by AZM treatment. Significant upregulation of pro-inflammatory markers correlated with FEV1 < 50% (TNFα, ECP, IL-21, IL-1, p = 0.01- 0.05), H. influenzae (HI) colonization (MPO, ECP, MIP-1, TNFα, IL-21, Il-8, IL-1, IL-1α, p < 0.001 – 0.04) and number of exacerbations (MPO, ECP, VEGF, MMP-9, p = 0.003 – 0.01). Surprisingly, colonization with P. aeruginosa (PA) was found to correlate with an attenuated inflammatory response compared to non-PA colonized. In placebo-treated patients, presence of an infectious exacerbation was reflected by a significant excessive increase in inflammation as compared to a non-significant upregulation in the AZM-treated patients. Conclusion: One year of AZM treatment did not result in attenuation of the inflammatory response in BE. Increasing disease severity and the presence of an exacerbation were reflected by upregulation of pro-inflammatory markers.


  • Open Access

    The effect of azithromycin on sputum inflammatory markers in bronchiectasis. Analysis from the BAT randomized controlled trial

    by L. C. Terpstra, J. Altenburg, H. J. Doodeman, Y. S. Sabogal Piñeros, R. Lutter, H. G. M. Heijerman, W. G. Boersma

    Background Long term macrolide treatment has been found beneficial in bronchiectasis (BE) -pathogical bronchial dilatation- possibly due to a combined anti-bacterial and immunomodulatory effect. The exact mechanism of inflammatory response is unknown. Here, we investigated the effect of maintenance macrolide treatment on the inflammatory response in BE. In addition, we assessed the inflammatory profile in BE in relation to disease severity. Methods During the BAT randomized controlled trial (investigating the effect of 1 year of azithromycin (AZM) in 83 BE patients), data on BE severity, lung function and sputum microbiology was collected. For the current study, a wide range of inflammatory markers were analysed in 3- monthly sputum samples in all participants. Results At baseline, marked neutrophilic but also eosinophilic inflammation was present in both groups, which remained stable throughout the study and was not affected by AZM treatment. Significant upregulation of pro-inflammatory markers correlated with FEV1 < 50% (TNFα, ECP, IL-21, IL-1, p = 0.01–0.05), H. influenzae (HI) colonization (MPO, ECP, MIP-1, TNFα, IL-21, Il-8, IL-1, IL-1α, p < 0.001–0.04) and number of exacerbations (MPO, ECP, VEGF, MMP-9, p = 0.003–0.01). Surprisingly, colonization with P. aeruginosa (PA) was found to correlate with an attenuated inflammatory response compared to non-PA colonized. In placebo-treated patients, presence of an infectious exacerbation was reflected by a significant excessive increase in inflammation as compared to a non-significant upregulation in the AZM-treated patients. Conclusion One year of AZM treatment did not result in attenuation of the inflammatory response in BE. Increasing disease severity and the presence of an exacerbation were reflected by upregulation of pro-inflammatory markers.

  • Open Access

    Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

    by Lotte C. Terpstra, Josje Altenburg, Inez Bronsveld, Martijn D. de Kruif, Yvonne Berk, Dominic Snijders, Wouter Rozemeijer, Harry G. M. Heijerman, Wim G. Boersma

    Background: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findings also suggest a benefit in non-CF bronchiectasis. We investigated the efficacy and safety of maintenance TIS once daily (OD) in frequent exacerbating bronchiectasis patients chronically infected by different pathogens sensitive for tobramycin. Objective: The primary outcome was the frequency of exacerbations during the 12-month study period. Secondary outcomes were time to first exacerbation, change in lung function and quality of life (QoL), bacterial analysis and safety. Materials/patients: In this multicenter RCT patients aged ≥ 18-year-old were included with confirmed bronchiectasis and ≥ 2 exacerbations in the preceding year. Patients were assigned (1:1) to receive TIS or placebo OD for 1-year.: Results: 58 patients were included of which 52 were analyzed in the mITT analysis. TIS reduced exacerbation frequency with a RR of 0.74 (95% CI 0.49–1.14) (p = 0.15). Within the TIS population a decrease in number of exacerbations was found (2; p = 0.00), which was also seen in the placebo-treated patients (1.5; p = 0.00). In the TIS-treated patients the QoL improved (LRTI-VAS p = 0.02 Leicester Cough p = 0.02) without additional safety concerns. No differences were found for the other secondary outcomes. Conclusion: Long-term TIS OD is a safe treatment modality and showed a non-significant reduced exacerbation frequency of 0.74 as compared to placebo in bronchiectasis patients chronically infected by tobramycin sensitive pathogens. TIS OD may be a potential therapeutic strategy in selected patients with bronchiectasis suffering from a high burden of disease. Trail registration number: The BATTLE study was registered at Clinical trials.gov number: NCT02657473. Date: 13 august 2016.


  • Open Access

    Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

    by L.C. Terpstra, J. Altenburg, I. Bronsveld, M.D de Kruif, Y. Berk, D. Snijders, W. Rozemeijer, H.G.M. Heijerman, W.G. Boersma

    Background: Use of long-term tobramycin inhalation solution (TIS) has been shown beneficial in cystic fibrosis (CF) and earlier findings also suggest a benefit in non-CF bronchiectasis. We investigated the efficacy and safety of maintenance TIS once daily (OD) in frequent exacerbating bronchiectasis patients chronically infected by different pathogens sensitive for tobramycin.Objective: The primary outcome was the frequency of exacerbations during the 12-month study period. Secondary outcomes were time to first exacerbation, change in lung function and quality of life (QoL), bacterial analysis and safety.Materials/patients: In this multicenter RCT patients aged ≥ 18-year-old were included with confirmed bronchiectasis and ≥ 2 exacerbations in the preceding year. Patients were assigned (1:1) to receive TIS or placebo OD for 1-year.Results: 58 patients were included of which 52 were analyzed in the mITT analysis. TIS reduced exacerbation frequency with a RR of 0.74 (0.49-1.14) (p=0.15). Within the TIS population a significant decrease in number of exacerbations was found (2; p=0.00), which was also seen in the placebo-treated patients (1.5; p=0.00). In the TIS-treated patients the QoL significantly improved (LRTI-VAS p=0.02 Leicester Cough p=0.02) without additional safety concerns. No significant differences were found for the other secondary outcomes.Conclusion: Although the predefined 50% reduction in number of exacerbations was not observed, long-term TIS OD is a safe and effective treatment modality in patients with bronchiectasis chronically infected by tobramycin sensitive pathogens. This could be a useful strategy in selected patients with bronchiectasis suffering from a high burden of disease.The BATTLE study was registered at Clinical trials.gov number: NCT02657473. Date: 13 aug 2016

  • The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial

    by Lotte C. Terpstra, Josje Altenburg, Firdaus A. Mohamed Hoesein, Inez Bronsveld, Shirley Go, Philip A.C. van Rijn, Pim A. De Jong, Harry G.M. Heijerman, Wim G. Boersma


  • Aetiology and disease severity are among the determinants of quality of life in bronchiectasis

    by Lotte C. Terpstra, Sonja Biesenbeek, Josje Altenburg, Wim G. Boersma

    Introduction Quality of life (QoL) is known to be impaired in patients with bronchiectasis, which is generally attributed to exacerbations and chronic pulmonary symptoms. The aim of this study was to determine if aetiology and disease severity are associated with QoL in bronchiectasis. Methods We conducted a retrospective analysis of clinical stable patients with bronchiectasis. Diagnostic workup into the aetiology of bronchiectasis was conducted according to the current guidelines. QoL was measured by QoL-B questionnaire (QoL-B), data on sputum microbiology, pulmonary function tests and the disease severity were obtained. Results The aetiology of bronchiectasis was investigated in the total of 200 patients. The most commonly identified aetiologies were post-infective (39.5%) and idiopathic (12.5%). Patients with chronic obstructive pulmonary disease (COPD)-related bronchiectasis showed a significant lower QoL (P < .05) as compared to the other aetiologies. In the total population, an increasing disease severity as measured by FACED, E-FACED and the bronchiectasis severity index was correlated with a lower QoL. Conclusions Our results showed that QoL in bronchiectasis is related both to aetiology, with worse QoL in COPD-related bronchiectasis, and to disease severity, which suggests more attention in advance for these specific patient groups with bronchiectasis.